Company intelligence / Profile preview

Fortress Credit Company

Bay Harbor Islands, Florida, United States

Ownership: Private
Development stage: Other

Overview

Fortress Biotech has achieved commercial stage with FDA approvals for Emrosi™ and UNLOXCYT™ as of 2025, along with marketed dermatology products. The company operates through a subsidiary model focusing on oncology, dermatology, and rare diseases.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Monoclonal antibodySmall moleculeProtein
Industry: Biotech

Partnerships

AstraZenecaCity of HopeFred Hutchinson Cancer CenterSun Pharma

Beyond the preview

Go deeper on Fortress Credit Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortress Credit Company.

Explore the full profile